Group 1 - Momentum investing focuses on "buying high and selling higher" rather than traditional "buying low and selling high" strategies [1] - Fast-moving stocks can lose momentum if their valuations exceed future growth potential, leading to potential downsides for investors [2] - A safer investment approach involves identifying bargain stocks with recent price momentum, utilizing tools like the Zacks Momentum Style Score [3] Group 2 - American Well Corporation (AMWL) has shown a significant price increase of 35.1% over the past four weeks, indicating strong investor interest [4] - Over the past 12 weeks, AMWL's stock gained 35.9%, and it has a beta of 1.28, suggesting it moves 28% more than the market [5] - AMWL has a Momentum Score of B, indicating a favorable time to invest based on its momentum [6] Group 3 - AMWL has received a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which typically attract more investors [7] - The stock is currently trading at a Price-to-Sales ratio of 0.53, indicating it is undervalued at 53 cents for each dollar of sales [7] - AMWL is positioned for further growth, and there are additional stocks that meet the criteria for fast-paced momentum at a bargain [8]

Financial Data and Key Metrics Changes - The meeting confirmed the presence of approximately 77.28% of the voting power from shareholders, indicating strong shareholder engagement [4] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on maintaining a robust investor relations program and providing high levels of accessibility to shareholders [3] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting included the election of directors and the ratification of the independent public accounting firm for the fiscal year 2025 [8][10] - The compensation for named executive officers was also discussed, with recommendations for approval [11][12] Q&A Session All Questions and Answers - No Q&A session was conducted during the meeting

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) emerging as key players in medical consultations and digital health solutions [1][2] Stock Performance & Valuation - HIMS has outperformed AMWL over the past three months, with a 35.1% increase compared to AMWL's 22.3% decline. In the past year, HIMS has rallied 183%, while AMWL has seen a decline of 20.3% [3] - HIMS is trading at a forward 12-month price-to-sales (P/S) ratio of 4.6X, above its three-year median of 2.3X. In contrast, AMWL's forward sales multiple is at 0.4X, below its median of 1.3X [4] Growth Potential for Hims & Hers - HIMS is expanding into new conditions treatable via telehealth, focusing on areas like sleep disorders and hypertension, which align with its business model [7] - HIMS has partnered with Novo Nordisk to enhance accessibility to obesity care, launching a six-month Wegovy access plan at $549/month [8] - Over 65% of new subscribers in 2024 benefited from personalized products, aided by the MedMatch AI tool for customized treatment plans [9] Growth Potential for Amwell - Amwell's platform allows clients to utilize their provider networks for virtual care across various modalities, from primary to specialty care [10] - The Converge platform enables care across in-person, virtual, and automated modalities, supporting interoperability with EHRs [11] - Amwell has a nationwide clinical coverage with around 1,000 active behavioral health providers and partnerships with organizations like the Cleveland Clinic [12] Earnings Projections - The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 166.7% improvement from 2024 [13] - The Zacks Consensus Estimate for AMWL's 2025 loss per share implies a 49.7% improvement from 2024 [15] Price Targets - The average price target for HIMS is $43.00, indicating a potential decline of 17.9% from the last close [17] - The average price target for AMWL is $10.00, suggesting a potential increase of 44.7% from the last close [18] Investment Recommendation - HIMS is viewed as a more stable and financially sound investment opportunity, with strong profitability and user engagement, generating substantial free cash flow [21] - AMWL is recognized for its rapid growth and expansion but is considered a lower-ranked investment option compared to HIMS [22]

Core Points - Amwell granted 3,451 RSUs of Class A common stock to a new employee as an inducement for employment, with a vesting schedule of 25% after one year and the remaining 75% vesting in equal increments every three months over three years [1][2] - The grants were approved by Amwell's Compensation Committee under the Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform supports various clinical programs and offers integrated solutions that are scalable, serving millions of patients and healthcare organizations globally [3]

Core Viewpoint - American Well Corporation (AMWL) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for American Well for the fiscal year ending December 2025 is projected at -$8.72 per share, reflecting a 37.2% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for American Well has increased by 5.7%, indicating a positive revision trend [8]. Zacks Rating System - The Zacks rating system is based on changes in earnings estimates, which are crucial for determining stock price movements, making it a valuable tool for investors [2][4]. - The system classifies stocks into five groups, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of American Well to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Core Viewpoint - American Well Corporation (AMWL) has seen an 11.8% increase in share price over the past four weeks, closing at $7.31, with a potential upside of 46.5% based on Wall Street analysts' mean price target of $10.71 [1][11]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $2.58, indicating variability among analysts [2]. - The lowest estimate is $7.50, suggesting a 2.6% increase, while the highest estimate predicts a surge of 105.2% to $15 [2]. - A low standard deviation signifies strong agreement among analysts regarding the stock's price direction [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about AMWL's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - Over the past 30 days, one estimate has increased, leading to a 6.7% rise in the Zacks Consensus Estimate for the current year [12]. - AMWL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Group 1 - American Well Corporation (AMWL) is performing better than the Medical sector with a year-to-date return of approximately 0.8%, while the sector has lost an average of 2.4% [4] - The Zacks Rank for American Well Corporation is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] - The Zacks Consensus Estimate for AMWL's full-year earnings has increased by 5.7% in the past quarter, reflecting improved analyst sentiment [4] Group 2 - American Well Corporation is part of the Medical Info Systems industry, which consists of 38 stocks and currently ranks 69 in the Zacks Industry Rank [6] - Stocks in the Medical Info Systems industry have gained about 8.4% year-to-date, indicating that AMWL is slightly underperforming its industry [6] - Claritev Corporation (CTEV), another stock in the Medical sector, has shown a year-to-date return of 44.6% and also holds a Zacks Rank of 2 (Buy) [5]

Core Insights - American Well Corporation (AMWL) reported revenue of $66.83 million for the quarter ended March 2025, reflecting a year-over-year increase of 12.3% and exceeding the Zacks Consensus Estimate by 11.18% [1] - The company's EPS was -$1.73, an improvement from -$5.00 in the same quarter last year, with a surprise of 44.01% compared to the consensus estimate of -$3.09 [1] Revenue Breakdown - Platform subscription revenue was $32.21 million, slightly below the average estimate of $32.89 million, but showed a year-over-year increase of 29.6% [4] - Other revenue reached $8 million, significantly surpassing the average estimate of $3.61 million, marking a year-over-year increase of 122.8% [4] - Revenue from visits was $26.63 million, which was above the average estimate of $23.70 million, but represented a year-over-year decline of 14.3% [4] Stock Performance - Over the past month, shares of American Well have returned +2.5%, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Group 1 - American Well Corporation (AMWL) reported a quarterly loss of $1.73 per share, significantly better than the Zacks Consensus Estimate of a loss of $3.09, and an improvement from a loss of $5 per share a year ago, resulting in an earnings surprise of 44.01% [1] - The company achieved revenues of $66.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 11.18% and showing an increase from $59.52 million in the same quarter last year [2] - American Well has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock's immediate price movement will largely depend on management's commentary during the earnings call, with American Well shares having increased by about 1.1% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$2.26 on revenues of $65.45 million, and for the current fiscal year, it is -$9.34 on revenues of $254.97 million [7] - The Medical Info Systems industry, to which American Well belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - Total revenue for Q1 was $66.8 million, a 12% increase compared to Q1 2024, and a 25% increase when normalizing for the sale of Amwell Psychiatric Care [23][24] - Subscription software revenue accounted for 48% of total revenue at $32.2 million, up 30% year-over-year [24][29] - Adjusted EBITDA improved to negative $12.2 million from negative $45.6 million in Q1 2024, reflecting ongoing cost reduction efforts [29] Business Line Data and Key Metrics Changes - The company completed approximately 1.3 million visits in Q1, which is about 23% lower than the previous year, but normalized visits were only 21% lower [25] - AMG's visit revenue trended 14.3% lower year-over-year at $26.6 million, but normalized visits were up 6.6% [26] - Average revenue per visit was $71, which is 8% lower compared to last year's Q1, but normalized revenue per visit was 8% higher [26] Market Data and Key Metrics Changes - The company is experiencing a shift towards technology-enabled care, with increasing consumer demand for online healthcare services [15][21] - The military health system is now fully utilizing the platform for virtual visits, positioning the company strongly in the federal market [11][12] Company Strategy and Development Direction - The company aims to achieve positive cash flow from operations by 2026, focusing on increasing the mix of subscription software revenues [6][30] - The recent hire of Dan Zemanski as Chief Product and Technology Officer is expected to enhance the company's technological capabilities and streamline consumer experiences [10][40] - The company is committed to driving efficiencies and optimizing cash flow while expanding its market presence [11][20] Management's Comments on Operating Environment and Future Outlook - Management noted that despite macroeconomic uncertainties, the demand for their platform is increasing as it provides significant ROI for clients [52][63] - The company remains confident in the renewal of its contract with the Defense Health Agency, which is expected to be finalized soon [32][70] - Management expressed optimism about the future, highlighting the potential for growth in technology-enabled care [21][35] Other Important Information - The company ended Q1 with $222 million in cash and marketable securities and zero debt [29] - The guidance for 2025 includes expected revenue in the range of $250 million to $260 million, with subscription revenue anticipated to represent nearly 60% of total revenues [30][31] Q&A Session Summary Question: Can you talk about bookings trends for CONVERGE and the impact of Dan's hire? - Management noted good receptivity to the platform beyond the DHA, with Dan's expertise expected to enhance consumer experience and data infrastructure [37][39] Question: Is the current gross margin rate sustainable for the rest of the year? - Management indicated that gross margins should improve as software revenues increase, with expectations of reaching 75-90% margins [44][45] Question: Have macroeconomic factors impacted sales timelines? - Management acknowledged market uncertainty but emphasized that their platform is seen as a solution to efficiency and revenue growth [51][53] Question: What is the status of the DHA contract and other government opportunities? - Management expects no significant changes in the economics of the DHA contract and highlighted the successful implementation of their platform across the military health system [56][58] Question: What is the company's direct exposure to tariffs? - Management stated that direct exposure to tariffs is minimal, as most hardware is sourced from third parties, and the business primarily focuses on software [62][63] Question: How is churn being managed, and what is the outlook for the selling season? - Management reported lower-than-expected churn and noted increased interest from both health systems and payers in their products [82][84]